Education
About Us
Working with TipRanks
Follow Us
Imugene Limited (AU:IMU)
ASX:IMU
IMU Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.09
Previous CloseN/A
Volume11.90M
Average Volume (3M)30.31M
Market Cap
$179.21M
Enterprise ValueAU$323.08M
Total Cash (Recent Filing)AU$2.46M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Aug 27, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding7,467,021,000
10 Day Avg. Volume22,559,538
30 Day Avg. Volume30,308,369
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Imugene Limited News
PremiumCompany Announcements
Imugene Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Imugene Limited Announces Cessation of Restricted Stock Units
PremiumCompany Announcements
Imugene Limited Issues New Restricted Stock Units to EmployeesPremiumCompany Announcements
Imugene Limited Announces Investor Webinar to Discuss Business UpdatesPremiumCompany Announcements
Imugene Advances Phase 1 onCARlytics Trial with Dose Escalation Clearance
PremiumCompany Announcements
Imugene’s Azer-cel Receives FDA Fast Track Designation for DLBCLPremiumCompany Announcements
Imugene Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Imugene Limited Reports Progress in Cancer Therapies---
Options Prices
Currently, No data available
---
Ownership Overview
7.27% Insiders
2.54%
Mutual Funds
<0.01% Other Institutional Investors
87.33% Public Companies and
Individual Investors
IMU FAQ
What was Imugene Limited’s price range in the past 12 months?
Imugene Limited lowest share price was AU$0.02 and its highest was AU$0.09 in the past 12 months.
What is Imugene Limited’s market cap?
Imugene Limited’s market cap is $179.21M.
When is Imugene Limited’s upcoming earnings report date?
Imugene Limited’s upcoming earnings report date is Aug 27, 2025 which is in 127 days.
How were Imugene Limited’s earnings last quarter?
Imugene Limited released its earnings results on Feb 27, 2025. The company reported -AU$0.007 earnings per share for the quarter, beating the consensus estimate of -AU$0.01 by AU$0.003.
Is Imugene Limited overvalued?
According to Wall Street analysts Imugene Limited’s price is currently Overvalued.
Does Imugene Limited pay dividends?
Imugene Limited does not currently pay dividends.
What is Imugene Limited’s EPS estimate?
Imugene Limited’s EPS estimate is -0.01.
How many shares outstanding does Imugene Limited have?
Imugene Limited has 7,467,021,000 shares outstanding.
What happened to Imugene Limited’s price movement after its last earnings report?
Imugene Limited reported an EPS of -AU$0.007 in its last earnings report, beating expectations of -AU$0.01. Following the earnings report the stock price went down -2.632%.
Which hedge fund is a major shareholder of Imugene Limited?
Currently, no hedge funds are holding shares in AU:IMU
---
Imugene Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IMU Sentiment 85%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.72%
12-Months-Change
Fundamentals
Return on Equity
-99.05%
Trailing 12-Months
Asset Growth
-52.38%
Trailing 12-Months
Company Description
Imugene Limited
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
---
IMU Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Biotron Limited
―
Mesoblast Limited
―
Telix Pharmaceuticals Ltd.
―
Race Oncology Ltd.
―
Proteomics International Laboratories Ltd.
―
Best Analysts Covering IMU
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-50.10%
reiterated a buy rating 12 months ago
Copying John Hester's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -50.10% per trade.
---